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Abstract 
Background 
Clinical trials have shown that trastuzumab, a recombinant monoclonal antibody against HER2 
receptor, significantly improves overall survival and disease-free survival in women with HER2-
positive early breast cancer, but long-term follow-up data are needed. We report the results of 
comparing observation with two durations of trastuzumab treatment at a median follow-up of 11 years, 
for patients enrolled in the HERA (HERceptin Adjuvant) trial. 
Methods 
HERA (BIG 1-01) is an international, multicentre, open-label, phase 3 randomised trial of 5102 
women with HER2-positive early breast cancer, who were enrolled from hospitals in 39 countries 
between Dec 7, 2001, and June 20, 2005. After completion of all primary therapy (including, surgery, 
chemotherapy, and radiotherapy as indicated), patients were randomly assigned (1:1:1) to receive 
trastuzumab for 1 year (once at 8 mg/kg of bodyweight intravenously, then 6 mg/kg once every 3 
weeks) or for 2 years (with the same dose schedule), or to the observation group. Primary endpoint is 
disease-free survival, and analyses are in the intention-to-treat population. Hazard ratios (HRs) were 
estimated from Cox models, and survival curves were estimated by the Kaplan-Meier method. 
Comparison of 2 years versus 1 year of trastuzumab is based on 366-day landmark analyses. This 
study is registered with ClinicalTrials.gov (NCT00045032). 
Findings 
Of the 5102 women randomly assigned in the HERA trial, three patients had no evidence of having 
provided written informed consent to participate. We followed up the intention-to-treat population of 
5099 patients (1697 in observation, 1702 in 1-year trastuzumab, and 1700 in 2-years trastuzumab 
groups). After a median follow-up of 11 years (IQR 10·09–11·53), random assignment to 1 year of 
trastuzumab significantly reduced the risk of a disease-free survival event (HR 0·76, 95% CI 0·68–
0·86) and death (0·74, 0·64–0·86) compared with observation. 2 years of adjuvant trastuzumab did 
not improve disease free-survival outcomes compared with 1 year of this drug (HR 1·02, 95% CI 
0·89–1·17). Estimates of 10-year disease-free survival were 63% for observation, 69% for 1 year of 
trastuzumab, and 69% for 2 years of trastuzumab. 884 (52%) patients assigned to the observation 
group selectively crossed over to receive trastuzumab. Cardiac toxicity remained low in all groups and 
occurred mostly during the treatment phase. The incidence of secondary cardiac endpoints was 122 
(7·3%) in the 2-years trastuzumab group, 74 (4·4%) in the 1-year trastuzumab group, and 15 (0·9%) 
in the observation group. 
Interpretation 
1 year of adjuvant trastuzumab after chemotherapy for patients with HER2-positive early breast 
cancer significantly improves long-term disease-free survival, compared with observation. 2 years of 
trastuzumab had no additional benefit. 
  
Introduction 
15–20% of patients with early breast cancer have tumours that exhibit overexpression, amplification, 
or both, of the HER2 receptor or oncogene, and the use of adjuvant trastuzumab (Herceptin; Roche, 
Basel, Switzerland) is now the standard of care for these patients. Four large randomised trials1–3 
have clearly shown that trastuzumab has a major effect in reducing recurrence and death in patients 
with this type of early breast cancer. Initial trials compared 1 year of trastuzumab treatment with a 
control group without trastuzumab.1–3 Longer follow-up confirmed a persistent benefit of 1 year of 
trastuzumab treatment versus observation (no trastuzumab).4–7 The HERA (HERceptin Adjuvant) 
trial1 randomly assigned patients to one of three groups: a control group, 1 year of trastuzumab, or 2 
years of trastuzumab. This trial is unique because it assigned patients to 2 years of trastuzumab. 
Demonstration that 2 years of trastuzumab was not more effective than 1 year of trastuzumab7 
reinforced the use of 1 year of treatment as the standard of care. Long-term follow-up of patients with 
HER2-positive breast cancer is important to better understand the true impact of this disease, the 
benefits of trastuzumab, and long-term cardiovascular safety. Here we report the results of the 
comparison between observation, 1 year of trastuzumab, and 2 years of trastuzumab treatment at a 
median follow-up of 11 years of patients enrolled within the HERA trial.1 
Research in context 
Evidence before this study 
We searched PubMed for randomised clinical trials published in English between Jan 1, 2000, and 
March 1, 2013, assessing long-term outcomes (>5 years' follow-up) from randomised trials of 
systemic therapy in patients with early breast cancer confirmed as HER2-positive, using the search 
terms “adjuvant”, “breast”, “randomised”, and “HER2”. We found no data in the published literature 
providing 10 years or more of follow-up from the use of adjuvant trastuzumab within a randomised 
trial. 
Added value of this study 
To our knowledge, this 11-year follow-up of the HERA trial provides the longest survival data of any 
trial that assessed the addition of anti-HER2 therapy to standard treatment for HER2-positive early 
breast cancer. We provide long-term patient outcome data to support the use of 1 year of adjuvant 
trastuzumab in this patient population, with evidence that those patients randomly assigned to receive 
trastuzumab (in both the 1-year and 2-years groups) sustained relative reductions in recurrence and 
breast cancer deaths, with the reassurance that the rate of serious toxicity does not increase over 
time. We also showed no evidence of a benefit of 2 years of trastuzumab compared with 1 year, and 
could not identify a subgroup of patients studied in the HERA trial who would not have derived long-
term benefits. 
Implications of all the available evidence 
Patients with HER2-positive early breast cancer who meet the criteria for the HERA trial (or the other 
studies reported elsewhere), including the cardiac disease criteria, we believe should be offered 1 
year of adjuvant trastuzumab as part of standard of care. Patients can be reassured that there are 
benefits in terms of better disease-free and overall survival that are sustained to at least 10 years 
after diagnosis, with no evidence of significant differential benefit by disease characteristics, such as 
nodal status or tumour hormone receptor status. Additionally, there is no evidence of late emergent 
side-effects, including no evidence of more cardiac endpoints emerging up to 10 years after 
treatment. 
 
 
 
Methods 
Study design, participants, and randomisation and masking 
HERA is an open-label, phase 3, randomised controlled trial; full details of the trial methods have 
been previously reported.1,5 Briefly, between Dec 7, 2001, and June 20, 2005, 5102 patients were 
recruited and randomly assigned (1:1:1) to three groups of observation (without trastuzumab), or 
adjuvant treatment of trastuzumab for 1 year or for 2 years.1 Methods used to generate the random 
allocation sequence, stratification factors, type of randomisation, approval of the protocol by local 
ethics committees at each hospital, and the need for each patient to give signed informed consent are 
described elsewhere.5 
The comparison of the trastuzumab groups versus observation was based on the intention-to-treat 
(ITT) principle, after exclusion of three patients (one from each group) because of no record of written 
informed consent (figure 1). The comparison of 2 years versus 1 year of trastuzumab was based on a 
12-month landmark analysis of the 3105 women who were alive and disease-free for at least 12 
months (366 days) after randomisation to one of the two trastuzumab groups.7 To be eligible to 
participate, participants had to provide written informed consent and have central laboratory (Kassel, 
Germany) confirmation of locally assessed HER2-positive disease and left ventricular ejection fraction 
(LVEF) of at least 55% after completion of all chemotherapy with or without radiotherapy (figure 1). 
Patients with node-negative disease were eligible for enrolment in the HERA trial if the pathological 
tumour size was larger than 1 cm. Adjuvant endocrine therapy for women with steroid hormone 
receptor-positive cancers was administered concomitantly with and after trastuzumab in accordance 
with local protocols (appendix). 
Procedures 
Patients assigned to receive trastuzumab received a dose once at 8 mg/kg of bodyweight 
intravenously, then at 6 mg/kg once every 3 weeks for either 1 year or 2 years depending on group 
assignment. All patients adhered to the same schedule of follow-up visits, during which the 
symptoms, side-effects (graded according to the National Cancer Institute Common Toxicity Criteria 
[NCI-CTC] version 2.0), and findings on clinical examination every 3 months and haematological and 
chemistry tests every 6 months were recorded for the first 2 years after randomisation. Therefter, 
clinical and laboratory assessments were scheduled to occur ever 6 months for years 3–5, and then 
once per year up to year 10. Annual chest radiography was required up to year 5 and annual 
mammography up to year 10. Study visits for individual patients continued for 10 years after 
randomisation with full recording of any breast cancer recurrences, contralateral breast cancer, and 
second primaries. Selected adverse events, such as cardiac endpoints, were also collected. For 
patients who were alive and disease-free at the 10-year follow-up visit, the calculation of disease-free 
survival included the additional follow-up time reported after 10 years and deaths reported during the 
additional follow-up period were noted as disease-free survival events. 
Cardiac monitoring in all three groups included clinical assessments and measurements of LVEF by 
either echocardiography or multiple gated acquisition (MUGA) scanning at baseline, at months 3, 6, 
12, 18, 24, 30, and 36, and annually thereafter up to 10 years from randomisation. A primary cardiac 
endpoint was defined as New York Heart Association (NYHA) class III or IV toxicity, confirmed by a 
cardiologist, and a clinically significant LVEF drop of at least 10 percentage points from baseline and 
to an absolute LVEF below 50%, or cardiac death. A secondary cardiac endpoint was defined as 
asymptomatic (NYHA class I) or mildly symptomatic (NYHA class II) with a clinically significant LVEF 
drop of at least 10 percentage points from baseline and to an absolute LVEF below 50% confirmed by 
repeat assessment. An algorithm was defined in the protocol (appendix) prescribing delay or 
cessation of trastuzumab in response to cardiac endpoints. 
Outcomes 
This analysis was a pre-planned, final efficacy analysis of the HERA trial. The primary endpoint was 
disease-free survival, as described previously.1 Events ending disease-free survival were almost 
identical to those used to define invasive disease-free survival (IDFS) using STEEP criteria.8 
Secondary endpoints included overall survival, sites of first relapse, competing-risk cumulative 
incidence analysis of breast cancer and non-breast cancer disease-free survival events, and cardiac 
safety. Additionally, a secondary endpoint was an efficacy analysis by local assessment of steroid 
hormone receptor status of the primary tumour. 
Safety, particularly cardiac safety, was also a secondary endpoint. Safety populations were generally 
defined according to randomised assignment. However, 20 patients assigned to 1 year of 
trastuzumab and 25 patients assigned to 2 years of trastuzumab were allocated to the observation 
safety population because they never received trastuzumab. Two additional patients randomly 
assigned to 2 years of trastuzumab—who initially refused trastuzumab but chose to receive 
trastuzumab after the release of the study results—are included in the observation safety population 
until the time that they started trastuzumab. The results from these two additional patients were 
included in the ITT analysis for 2 years of trastuzumab group, but censored in the safety analysis. 
Adverse events were assessed from the time of randomisation. Adverse events, including cardiac 
endpoints, recorded after crossover of patients in the observation group to trastuzumab were 
excluded. 
Statistical analysis 
This updated comparison of 1 year of trastuzumab versus observation was based on 1702 patients 
enrolled in the 1 year trastuzumab group and 1697 patients in the observation group, using an ITT 
analysis from the time of randomisation. 884 (52%) of the 1697 patients in the observation group 
selectively crossed over to receive trastuzumab after the release of the initial results of this trial1 and 
other trials2 in 2005, of whom 477 (54%) had hormone-receptor-positive disease and 407 (46%) had 
hormone-receptor-negative disease (data not shown). As previously described,5 the selective 
crossover improved outcomes for the observation group in the ITT analysis, resulting in an 
underestimation of the true trastuzumab treatment effect that would have been seen if no selective 
crossover had occurred. 
Log-rank tests for time-to-event endpoints provided two-sided p values. Kaplan–Meier curves are 
presented.9 Cox proportional hazards modelling was used to estimate unadjusted hazard ratios (HRs) 
and 95% CIs.10 The cumulative incidence of cardiac endpoints based on competing risks was 
calculated.11 Exploratory Cox modelling was done to examine interactions between treatment 
assignment, hormone receptor status, and time on study. Time-varying covariate Cox modelling11 
was used to explore the effect of selective crossover on the risk of a disease-free survival event in the 
observation control group. 
The comparison of 2 years versus 1 year of trastuzumab was based on a 12-month landmark analysis 
involving the 3105 women who were alive and disease-free for at least 12 months after randomisation 
to one of the two trastuzumab group. This study is registered with ClinicalTrials.gov, number 
NCT00045032. 
Role of the funding source 
The study was conducted under the auspices of the Breast International Group (BIG) and involved the 
collaboration of 17 BIG groups, nine other cooperative groups, 91 independent centres, and Roche 
(the sponsor), all of which were represented in the Steering Committee of the HERA trial. The study 
was designed by members of the HERA Steering Committee.1 The database was maintained at the 
Breast European Adjuvant Study Team (BrEAST) Data Centre (Brussels, Belgium). For the final data 
analysis, the HERA Executive Committee, on behalf of the HERA Steering Committee, had final 
responsibility for the decision to submit for publication and for the content of the manuscript. The 
sponsor provided the drug, some site monitoring, and financial support. 
 
 
Results 
Figure 1 shows the trial profile. Three patients had no record of written informed consent and were 
excluded from analyses. The three groups were well balanced with respect to demographics and 
baseline disease characteristics including tumour size and nodal and hormone receptor status (table 
1). 
Overall 2571 (50%) patients had hormone-receptor-positive disease and 2528 (50%) had hormone-
receptor-negative disease by local laboratory determination of hormone receptors. 2370 (92%) of the 
2571 hormone-receptor-positive cases received adjuvant endocrine therapy. Most patients received 
chemotherapy only postoperatively, but 563 (11%) patients had preoperative neoadjuvant 
chemotherapy. Chemotherapy included an anthracycline for 4797 (94%) patients, and an 
anthracycline and taxane for 1328 (26%) patients. 1646 (32%) patients had node-negative disease. 
Overall 2642 (52%) patients were aged 49 years or younger at the time of study entry. Patients in the 
HERA study started trastuzumab at a median of 8·4 months (IQR 7·1–9·6) after initial diagnosis of 
breast cancer and a median of 89 days (46–112) after completing all chemotherapy. 
In this final report, results for 1 year of trastuzumab (median of 18 cycles of once every 3 weeks [one 
cycle]) versus observation were based on 1113 disease-free survival events (1103 [99%] satisfied the 
STEEP criteria for IDFS events) and 725 patients deaths (an overall survival event). 884 (52%) 
patients in the observation group received trastuzumab before a disease-free survival event due to 
selective crossover after publication of the initial trial results. Despite this selective crossover, using 
an ITT analysis, after a median 11 years of follow-up the HR was 0·76 (95% CI 0·68–0·86) for 1-year 
trastuzumab versus observation. For those receiving 2-years trastuzumab (35 cycles median of once 
every 3 weeks) versus observation the HR was similar at 0·77 (95% CI 0·69–0·87). There were 1126 
disease-free survival events for the 2-years trastuzumab versus observation. 10-year disease-free 
survival was higher in the trastuzumab groups, with 63% in the observation group, 69% in the 1-year 
trastuzmab group, and 69% in the 2-years trastuzumab group (figure 2A). These figures 
corresponded with an absolute benefit of 6·8% in disease-free survival at 10 years for those receiving 
1-year trastuzumab and 6·0% for those receiving 2-years trastuzumab compared with the observation 
group. Of note in interpreting the ITT analysis is the fact that about half of the follow-up time in the 
observation group was accrued after selective crossover to trastuzumab. The annualised hazard rates 
for disease-free survival over time are in the appendix. The exploratory time-varying covariate Cox 
model showed that selective crossover was associated with a reduction in risk of a disease-free 
survival event in the observation group (HR 0·79, 95% CI 0·64–0·98; appendix). Selective crossover 
was associated with a numerically lower effect for the hormone-receptor-positive cohort (HR 0·92, 
95% CI 0·70–1·22) than for the hormone-receptor-negative cohort (0·69, 0·53–0·91, 
pinteraction=0·10; appendix). 
Kaplan-Meier plots of disease-free survival (DFS) over time are shown for all the intention-to-treat 
(ITT) population (A), for patients with hormone-receptor-positive disease (C), and for patients with 
hormone-receptor-negative disease (E). Cumulative incidence plots for breast cancer and non-breast 
cancer competing risks are shown for all the ITT population (B), for the hormone-receptor-positive 
cohort (D), and the hormone-receptor-negative cohort (F). Non-breast cancer DFS events are non-
breast malignancy and death without previous event. HR=hazard ratio. 
In the hormone-receptor-positive cohort, the HR (1-year trastuzumab vs observation) was 0·80 (95% 
CI 0·68–0·96) and the absolute benefit in 10-year disease-free survival rate was 5·6%. The 10-year 
disease-free survival was 66% in the observation group, compared with 72% in the 1-year 
trastuzumab and 70% in the 2-years trastuzmab groups (figure 2C). In the hormone-receptor-negative 
cohort, the 10-year disease-free survival rates were lower; 59% for the observation group, 67% for 1-
year trastuzumab group, and 67% for 2-years trastuzumab group. The HR for 1-year trastuzumab 
versus observation was 0·73 (95% CI 0·62–0·85) and the absolute benefit in 10-year disease-free 
survival was 8·0% (figure 2E). Exploratory Cox models compared trastuzumab (both 1 year and 2 
years combined) versus observation and indicated that time since randomisation was significantly 
associated with treatment effect for both hormone-receptor-positive and hormone-receptor-negative 
populations (appendix). HRs for early disease-free survival events (<24 months after randomisation) 
were 0·63 (95% CI 0·52–0·77) for hormone-receptor-positive and 0·59 (0·50–0·70) for hormone-
receptor-negative cohorts (appendix). Corresponding HRs for later disease-free survival events (≥24 
months after randomisation) were 0·98 (95% CI 0·82–1·16) for hormone-receptor-positive and 0·91 
(0·76–1·09) for hormone-receptor-negative cohorts (appendix). 
Subgroup analyses of disease-free survival by nodal status are in the appendix. Disease-free survival 
was worse for patients with higher numbers of positive axillary lymph nodes. In the 1-year 
trastuzumab group, the 10-year disease-free survival was 80% for the node-negative cohort, 75% for 
the cohort with one to three positive nodes, and 55% for the cohort with four or more positive nodes. 
HRs (1-year trastuzumab vs observation) were 0·78 for the node-negative cohort, 0·64 for those with 
one to three positive nodes, and 0·82 in those with four or more positive nodes. 
Table 2 shows the site of first disease-free survival event. The cumulative incidence curves of the 
competing risk of a disease-free survival event related to breast cancer and of a disease-free survival 
event not related to breast cancer are shown in figure 2 (B, D, and F). A lower numerical cumulative 
incidence of disease-free survival events related to breast cancer occurred in each of the trastuzumab 
groups than in the observation group for both the hormone-receptor-positive and hormone-receptor-
negative cohorts. The cumulative incidence of breast cancer-related disease-free survival events was 
numerically lower in the hormone-receptor-positive cohort, and with a smaller absolute decrease in 
the trastuzumab groups, than in the hormone-receptor-negative cohort. No numerical decrease in the 
incidence of non-breast cancer-related disease-free survival events was noted in either the hormone-
receptor-positive or hormone-receptor-negative cohorts. While a clinical benefit of trastuzumab was 
noted in both the hormone-receptor-positive and hormone-receptor-negative cohorts, the timing and 
rate of disease-free survival events appears different between these cohorts (figure 2D and 2F). 
As with disease-free survival, the results for overall survival also showed a robust and persistent 
improvement despite the effect of selective crossover (figure 3). The HR (1-year trastuzumab vs 
observation) for overall survival at 11 years of median follow-up was 0·74 (95% CI 0·64–0·86). At 12 
years, the overall survival was 73% in the observation group, 79% in the 1-year trastuzumab group, 
and 80% in the 2-years trastuzumab group. The absolute benefit in 12-year overall survival was 6·5% 
for 1-year trastuzumab and 6·6% for 2-years trastuzumab (appendix). 
In consideration of the overall survival in the hormone-receptor-positive cohort, the HR (1-year 
trastuzumab vs observation) was 0·81 (95% CI 0·65–1·00). At 12 years, the overall survival was 76% 
in the observation group, 81% in the 1-year trastuzumab group, and 81% in the 2-years trastuzumab 
group (appendix). In the hormone-receptor-negative cohort, overall survival at 12 years was lower 
than in the hormone-receptor-positive cohort, with 70% for the observation group, 78% for the 1-year 
trastuzumab group, and 79% for the 2-years trastuzumab group. The HR for 1-year trastuzumab 
versus observation was 0·70 (95% CI 0·57–0·85; appendix). 
No new safety concerns have emerged since previous reports.5,7 More patients had at least one 
grade 3 or 4 adverse event in the trastuzumab groups (295 [18%] in 1-year trastuzumab; 364 [22%] in 
2-years trastuzumab) than in the observation group (152 [9%]; appendix). Primary cardiac endpoints 
were very rare in this study, which introduced trastuzumab after completing all chemotherapy and 
radiation therapy and required a post-chemotherapy LVEF of at least 55% before enrolment. No 
significant difference was noted in the occurrence of primary cardiac endpoints between the two 
trastuzumab groups, although the frequency of events was higher than in the observation group (two 
[0·1%] in the observation group, 18 [1%] in the 1-year trastuzumab group, and 17 [1%] in the 2-years 
trastuzumab group; figure 4; appendix). Secondary cardiac endpoints occurred more frequently in the 
2-years trastuzumab group (122 [7·3%]) than in the 1-year trastuzumab group (74 [4·4%]) and the 
observation group (15 [0·9%]; figure 4; appendix). In both trastuzumab groups fewer cardiac 
endpoints occurred after the completion of trastuzumab treatment than in the scheduled treatment 
period (figure 4). There was no evidence of a clinically significant number of cardiac endpoints 
occurring after a long time since randomisation (up to 10 years; figure 4). 
Compliance with randomised assignment of trastuzumab duration was generally good.7 The update 
of the landmark analysis comparison of 2 years versus 1 year of trastuzumab was based on 814 
disease-free survival events. There was no evidence of a long-term benefit of 2 years compared with 
1 year of trastuzumab when administered as sequential treatment after chemotherapy (HR for 
disease-free survival 1·02, 95% CI 0·89–1·17; appendix). The short-term separation in the disease-
free survival curves in the hormone-receptor-negative cohort was not significant (appendix), for which 
the long-term HR was 0·94 (95% CI 0·77–1·14; appendix). In the hormone-receptor-positive cohort 
the long-term HR was 1·10 (0·91–1·34; appendix). 
 
 
 
Discussion 
After 11 years of median follow-up, the use of 1 year of adjuvant trastuzumab significantly improves 
disease outcomes when given in addition to standard of care, including chemotherapy, in patients 
with HER2-positive early breast cancer. The relative risk of a disease-free survival event is reduced 
by 24% from when trastuzumab is given in addition to standard of care, conferring an absolute benefit 
of 6·8% improvement in 10-year disease-free survival in those women who were randomly assigned 
to 1-year trastuzumab group compared with those assigned to the observation group. Furthermore, a 
6·5% absolute gain was found in overall survival at 12 years between those in the 1-year trastuzumab 
group versus those in the observation group. As previously noted,5 since just over half the patients in 
the observation group crossed over to receive trastuzumab after release of the initial results of the 
HERA trial, these estimates of absolute benefit are probably underestimates of the true benefit for 
patients. In fact, in this analysis selective crossover was associated with a 21% relative reduction in 
the risk of a disease-free survival event in the observation group, thus clearly attenuating the 
trastuzumab effect estimated by the ITT analysis. Furthermore, trastuzumab treatment effects were 
significantly greater during the first 24 months after randomisation than during follow-up, a finding 
which might be partly attributable to crossover. 
Subgroup analysis by tumour hormone receptor status shows two important observations. First, 
despite overexpression of the HER2 oncogene, hormone receptor status remains a powerful 
determinant of disease outcome, with more recurrences and deaths in women with hormone-receptor-
negative disease even after 11 years' median follow-up. Furthermore, our data suggest that the timing 
of recurrences is different, with an initial higher frequency of disease-free survival events in patients 
with hormone-receptor-negative disease than those with hormone-receptor-positive disease, although 
events still accumulate up to 10 years after randomisation in both cohorts. Table 2 reports the sites of 
first recurrence, which clearly shows that all sites of recurrence were slightly more frequent in patients 
with hormone-receptor-negative HER2-positive breast cancer, with the exception of skeletal distant 
recurrence, in keeping with previous reports in non-HER2-positive disease. Second, there is no 
evidence that the efficacy of trastuzumab is different according to the hormone-receptor status of the 
primary tumour. Numerically the HR was larger in those women with hormone-receptor-positive 
disease (0·80) than those with homone-receptor-negative disease (0·73; comparing 1-year 
trastuzumab vs observation), but the difference was not significant and could have been affected by 
the higher percentage of hormone-receptor-positive cases who could cross over due to lower risk of 
early relapses. Benefit of trastuzumab was also noted in overall survival in both hormone-receptor 
groups, with lower HRs for 1-year trastuzumab versus observation in the hormone-receptor-negative 
cohort (0·70) than for the hormone-receptor-positive cohort (0·81). 
In earlier reports,5 there was evidence of progressively smaller apparent benefits of 1 year of 
trastuzumab in ITT analyses previously reported at 2-year and 4-year median follow-up. The HR for 
disease-free survival for 1-year trastuzumab versus observation, however, has been stable since 4-
year median follow-up (HR 0·76; figure 3). The results show a robust and persistent improvement in 
disease-free survival despite the effect of selective crossover (figure 3). Despite the increased 
tendency for patients with hormone-receptor-positive disease to have relapsed later than patients with 
hormone-receptor-negative disease, the estimated HRs for disease-free survival benefit stabilised at 
about 4 years of follow-up in both hormone receptor cohorts, suggesting a substantial and permanent 
effect of 1 year of trastuzumab on micrometastatic disease. 
In all analyses of the 1-year trastuzumab group versus observation group for overall survival, fewer 
deaths were reported in women with hormone-receptor-positive disease than those with hormone-
receptor-negative disease. About half of the women enrolled into the HERA trial had hormone-
receptor-positive disease, whereas the true proportion in an incident breast cancer population could 
be nearer to 60%.12 Thus this difference in timing of events, particularly for overall survival, means 
that interpretation of more recent clinical trials of adjuvant therapy in this patient population might 
need a more cautious analysis. If the true benefit in the majority population, which are hormone-
receptor-positive tumours, takes longer to appear than hormone-receptor-negative tumours, earlier 
analyses of overall survival could result in false negative conclusions. 
This report includes an updated analysis of a unique feature of the HERA trial, namely addressing the 
duration question by randomly assigning a third of the patients to a longer, 2-years duration of 
trastuzumab. The earlier report7 found no advantage for the longer duration of therapy compared with 
1 year of therapy, and is supported by the results from this longer-term analysis. This finding has real 
clinical relevance because there is no evidence that subjecting women to longer therapy with 
trastuzumab is the way to further reduce the risk of relapse and death from HER2-positive early 
breast cancer. Data from several studies, including those in the neo-adjuvant and metastatic disease 
settings,12–15 all indicate that greater anti-tumour activity is seen with the combination of two anti-
HER2 agents. However, the first report from the ALTTO study of the small molecule HER2 inhibitor 
lapatinib combined with 1 year of trastuzumab12 did not find a clinically significant benefit. The only 
other study that has reported outcomes for longer than 1 year's anti-HER2 therapy was the ExteNET 
study.16 The ExteNET study tested the benefit of 1 year of a small molecule, pan-HER2, tyrosine 
kinase inhibitor after 1 year of trastuzumab treatment, and the design was altered during the study to 
report events at 2 years' follow-up in all patients and thus does not have long-term outcome data 
comparable to those reported here for HERA. 
This updated analysis of the HERA study again indicates that a temporary benefit in disease-free 
survival might exist in those patients with hormone-receptor-negative disease who were randomly 
assigned to 2 years of trastuzumab compared with the 1 year of trastuzumab group. This result could 
be due to chance, but with other emerging data it does pose the hypothesis that there might be other 
ways to enhance the efficacy of this drug in the adjuvant setting. For women with hormone-receptor-
positive tumours, even when HER2 overexpressing, at least 5 years of adjuvant endocrine therapy is 
standard of care. This study and others3,6 substantiate that despite this extended anti-tumour 
therapy, trastuzumab gives clear additional benefit if given for 1 year, but once this drug is stopped 
the tumours are generally still subjected to active, anti-cancer endocrine therapy. By contrast, for 
those patients whose tumours are hormone-receptor-negative, once the trastuzumab is stopped and 
systemic levels fall, no anti-tumour therapy is given. Part of the efficacy of trastuzumab might be due 
to its ability to induce an immunologically mediated anti-tumour effect,17 which raises the possibility 
that concurrent modulation of the immune system, rather than further treatment with an anti-HER2 
drug, could be of benefit. One might further conjecture that the transient short-term benefit noted from 
additional trastuzumab after 1 year is because the extended high antibody levels maintain that 
immune recruitment, but to an insufficient degree to effectively eradicate microscopic disease. In 
patients with hormone-receptor-positive disease, the prolonged anti-endocrine therapy might mask 
the signal of any additional temporary benefit from immune enhancement. Finally, it could be 
hypothesised that the addition of drugs that enhance the immune anti-tumoural effect during the first 
year of therapy could be of real benefit if given in conjunction with trastuzumab acting as the potential 
recruiter of that immune response. 
A further important finding from this 11-year follow-up analysis is the safety of adjuvant trastuzumab. 
The unique feature of HERA is that serial LVEF assessment up to 10 years was completed in all 
patients, which provides more complete cardiac information than other reported adjuvant trastuzumab 
trials. No new safety signals have emerged despite the extended follow-up, and, particularly, no signal 
of late cardiac problems emerged, despite the ageing by a decade of the cohort in follow-up that 
subjected patients to an increased risk of age-related cardiac morbidity. For women who were 
randomly assigned to receive 2-years trastuzumab, more low-level cardiac endpoints were reported 
during treatment than for those receiving 1 year of this drug. However, it is reassuring that the 
frequency of cardiac endpoints during the second year of trastuzumab treatment was similar to that 
observed during the first year, with few cardiac endpoints reported after 2 years, and evidence 
showing that those that did occur were mostly reversible.18 In view of the study eligibility criteria, it is 
not very surprising that primary cardiac endpoints were rare because the study population was at a 
low risk for these events. 
The selective crossover of just over half of the control group patients is a clear limitation of this 
extended follow-up ITT analysis of the HERA trial, although it is likely to provide an underestimate of 
the long-term efficacy of adjuvant trastuzumab. The absence of access to all primary tumour samples 
precludes exploratory translational analyses that could allow for an increased understanding of the 
biology of those tumours that relapse despite the use of adjuvant trastuzumab, and thus facilitate 
development of additional therapeutic approaches that could be beneficial. 
In conclusion, long-term follow-up of practice-changing clinical trials, such as the HERA trial,1 is 
essential to inform doctors and patients about the full range of benefits and burdens associated with 
new widely-adopted treatments. This analysis at a median follow-up of 11 years showed a 24% 
relative reduction in risk of a disease-free survival event, and a 26% relative reduction in risk of death, 
with the addition of 1 year of adjuvant trastuzumab in women with HER2-positive early breast cancer. 
There is no evidence of an additional benefit from a second year of trastuzumab, but some evidence 
exists of additional cardiac toxicity with longer duration of treatment. These results have been stable 
during the past several years of additional follow-up. The benefits of 1 year of adjuvant trastuzumab 
are substantial for both individual patients and breast cancer populations, and might even be 
underestimated due to the crossover of half of the observation group to receive trastuzumab. The 
benefits of trastuzumab treatment are noted irrespective of node status and tumour steroid hormone 
receptor status, although the absolute benefits for an individual do depend on their underlying risk of 
recurrence after other standard therapies. The HERA study therefore shows that 1 year of 
trastuzumab is an important, and curative, part of the standard of care for women with HER2-positive 
early breast cancer. 
 
 
 
  
TABLES 
 
Table 1. Baseline demographic and disease characteristics of patients, in the intention-to-treat 
population 
 
Data are n (%). ER=oestrogen receptor. PgR=progesterone receptor. 
* One patient with missing nodal status in the observation group. 
† One patient in the 1-year trastuzumab group with unknown oestrogen status and PgR-positive status. 
‡ Also includes patients with ER negative and PgR unknown. 
Table 2. Site of first disease-free survival event 
 
 
 
* In cases with multiple simultaneous sites of first event, a hierarchy assigned the event to the first applicable 
category in order of distant recurrence, regional recurrence, local recurrence, contralateral breast cancer, and 
second (primary) malignancy. 
† In cases with multiple simultaneous sites of distant recurrence as first event, a hierarchy assigned the type of 
distant recurrence in order of CNS, visceral, skeletal, soft tissue. 
‡ Includes contralateral invasive disease or ductal carcinoma in situ; there are four disease-free survival events of 
contralateral DCIS in the intention-to-treat population (two in the hormone-receptor-positive cohort and two in the 
hormone-receptor-negative cohort), which are not invasive disease-free survival (IDFS) events under the STEEP 
definition.8 
§ Includes second (non-breast) malignancies, invasive ipsilateral tumours of a different type from the primary breast 
cancer and ipsilateral DCIS events; it does not include contralateral breast cancer of any kind. 
¶ Eight disease-free survival events of an ipsilateral tumour of a different type from the primary breast cancer 
reported, which are not IDFS events under the STEEP definition. 
‖ Three disease-free survival events of an ipsilateral tumour of a different type from the primary breast cancer exist, 
which are not IDFS events under the STEEP definition. 
** Five disease-free survival events of an ipsilateral tumour of a different type from the primary breast cancer exist, 
which are not IDFS events under the STEEP definition. 
 
 
  
FIGURES 
 
Figure 1. Trial profile 
 
IHC=immunohistochemistry. FISH=fluorescence in-situ hybridisation. LVEF=left ventricular ejection fraction. 
ITT=intention to treat. 
 
 
 
 
 
Figure 2. Kaplan-Meier and cumulative incidence plots for DFS 
 
 
 
Kaplan-Meier plots of disease-free survival (DFS) over time are shown for all the intention-to-treat (ITT) 
population (A), for patients with hormone-receptor-positive disease (C), and for patients with hormone-receptor-
negative disease (E). Cumulative incidence plots for breast cancer and non-breast cancer competing risks are 
shown for all the ITT population (B), for the hormone-receptor-positive cohort (D), and the hormone-receptor-
negative cohort (F). Non-breast cancer DFS events are non-breast malignancy and death without previous event. 
HR=hazard ratio. 
 
Figure 3. 1 year trastuzumab versus observation, in the ITT population 
 
 
Disease-free survival (DFS) for the entire intention-to-treat (ITT) population (A), for patients with hormone-
receptor-positive disease (C), and those with hormone-receptor-negative disease (E). Overall survival for the 
entire ITT population (B), for the hormone-receptor-positive cohort (D), and for the hormone-receptor-negative 
cohort (F). These ITT analyses are affected by selective crossover in 884 (52%) patients from the observation 
group who received trastuzumab after the first trial results1 were published in 2005. HR=hazard ratio. *The 
percentages are of follow-up time in the ITT analysis that was accrued after selective crossover for patients 
assigned to the observation group. Figure reproduced and modified from Goldhirsch and colleagues, by 
permission of Elsevier.7 
 
 Figure 4. Cumulative incidence of cardiac endpoints 
 
 
 
Competing risk analysis showing the cumulative incidence of cardiac endpoints with disease-free survival events 
considered as competing risks. Primary (severely symptomatic) cardiac endpoint (A) and primary and secondary 
cardiac endpoints (B). 
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